Correction: Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 Week results of the SIMRIKI retrospective study (PLoS ONE (2016) 11:10 (e0164455) DOI: 10.1371/journal.pone.0164455)

  1. Troya, J.
  2. Ryan, P.
  3. Ribera, E.
  4. Podzamczer, D.
  5. Hontañón, V.
  6. Terrón, J.A.
  7. Boix, V.
  8. Moreno, S.
  9. Barrufet, P.
  10. Castaño, M.
  11. Carrero, A.
  12. Galindo, M.J.
  13. Suárez-Lozano, I.
  14. Knobel, H.
  15. Raffo, M.
  16. Solís, J.
  17. Yllescas, M.
  18. Esteban, H.
  19. González-García, J.
  20. Berenguer, J.
  21. Imaz, A.
Journal:
PLoS ONE

ISSN: 1932-6203

Year of publication: 2017

Volume: 12

Issue: 2

Type: Erratum

DOI: 10.1371/JOURNAL.PONE.0172184 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus